ANN ARBOR, Mich., July 21 /PRNewswire/ -- Terumo Cardiovascular Systems
and Spencer Technologies have signed agreements in which Terumo Cardiovascular
Systems is awarded global rights to market and distribute Spencer
Technologies' current offering of diagnostic ultrasound products for
cardiology and neurology applications and future products co-developed by the
two companies. The two companies have been engaged in similar agreements for
monitoring products in the cardiac surgery market since 2002.
Spencer Technologies manufactures the PMD100 Digital Transcranial Doppler
System, an enhanced ultrasound system for measurement of cerebral flow
velocity and emboli detection. The system is used for neurovascular
diagnosis, and has also been used as part of a protocol for the detection of
patent foramen ovale (PFO), a hole in the wall that separates the upper right
and left chambers of the heart. PFO has been associated with stroke,
transient ischemic attacks (TIAs) and migraine headaches.
Terumo Cardiovascular Systems has created a Neurovascular Monitoring
Business Unit to provide current and future diagnostic ultrasound devices to
the cardiology and neurology markets. The new business unit will be managed
by Kevin Hoffman, who also manages the company's Intraoperative Monitoring
Business Unit that has been engaged in applications for cardiac surgery.
As indicated by Hoffman, "Terumo Cardiovascular Systems is excited to
leverage our monitoring and marketing expertise with Spencer's research and
technical capabilities in providing unique solutions to address unmet
diagnostic needs. Together, we will enhance the quality of patient care in
The PMD100's digital technology represents a number of improvements over
traditional analog ultrasound technology, including increased accuracy and
ease of use. According to Mark Reisman, MD, Director of Cardiovascular
Research at Swedish Medical Center in Seattle, "The technology enables break-
through applications in diagnosis and treatment of stroke and provides a
flexible base for many future diagnostic and monitoring applications in
cardiology, vascular surgery, and neurology."
"After several years of dedicated research and development of our new
platform technology, we are thrilled to have Terumo Cardiovascular Systems
deliver it into the hands of health care providers worldwide. We know that
our unique technology can make a significant clinical difference, and
potentially save and improve the quality of many lives," said Scott Seidel,
CEO of Spencer Technologies.
Spencer Technologies was co-founded in 1992 by Dr. Merrill Spencer, a
pioneer in the development of diagnostic ultrasound. Spencer Technologies is
dedicated to preventing a variety of adverse cardiovascular related events,
including strokes, and significantly improving healthcare through the
development and use of non-invasive ultrasound technologies for diagnosis,
monitoring, and therapeutic effects.
Terumo Cardiovascular Systems Corporation manufactures and markets
products for the cardiac surgery, interventional, and neurovascular markets.
It is headquartered in Ann Arbor, Michigan with manufacturing operations in
Ann Arbor, as well as Elkton, Maryland; Ashland, Massachusetts; Tustin,
California; and Matamoros, Mexico. It is a subsidiary of Terumo Corporation
of Japan. Terumo Corporation is a premier global medical company with 2003
annual sales in excess of $1.9 billion. Terumo Corporation develops,
manufactures, and markets a wide range of medical products including syringes,
needles, catheters, and blood bags.
SOURCE Terumo Cardiovascular Systems